Hormone therapy has been a major treatment for advanced prostate cancer.This therapy aims at inhibiting growth of prostate tumor cells by deprivation of male hormones which stimulate prostate cells to grow.However, in spite of its temporally high effectiveness for tumor regression, most patients suffer from a relapse within a few years after initiation of treatment.The main cause of relapse is that cancer cells become resistant to hormone suppression.The toxicities of androgen deprivation have been well described, with a number of potential adverse effects on quality of life, including sexual dysfunction, hot flashes, fatigue, anemia, decreased bone density and muscle mass, altered blood lipid profile, depression, cognitive dysfunction, and worsening of the metabolic syndrome with effects on glucose metabolism and cardiovascular morbidity.